Recent developments highlight the expanding therapeutic applications of GLP-1 medications, traditionally used for diabetes and obesity. A study indicates that patients who experience interruptions in GLP-1 access still achieve notable weight loss, underscoring the treatment's efficacy when combined with medication, coaching, and lifestyle changes. Additionally, an elite rehabilitation center in Pennsylvania is pioneering the use of GLP-1 drugs, such as Ozempic, to address various forms of addiction, reporting promising results in reducing cravings. This approach is considered a paradigm shift in addiction treatment, with clinical trials currently underway to validate these findings. Furthermore, a propensity-matched cohort study from TriNetX reveals that GLP-1 users with intracranial hypertension show reductions in medication use, symptoms, and procedural interventions, independent of weight changes. These findings suggest broader benefits of GLP-1 therapies beyond metabolic conditions, including potential impacts on neurological and addictive disorders.